SCHEMBL10044940

SCHEMBL10044940

CNc1cc(OC)ccc1CCCN(C)C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 1/20 0.53
PIK3CG P48736 1/20 0.44
HTR2A P28223 3/20 0.43
HTR6 P50406 5/20 0.43
HTR2C P28335 2/20 0.43
HTR2B P41595 2/20 0.43
HTR3E A5X5Y0 1/20 0.43
HTR3B O95264 1/20 0.43
CYP1A2 P05177 1/20 0.43
HTR1A P08908 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
HTR1D P28221 1/20 0.43
HTR1B P28222 1/20 0.43
HTR1E P28566 1/20 0.43
HTR1F P30939 1/20 0.43
HTR7 P34969 1/20 0.43
HTR3A P46098 1/20 0.43
HTR5A P47898 1/20 0.43
MTNR1A P48039 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9740781 0.81 ESR1 (0.41) SLC6A4PIK3CGHTR2AMTNR1AMTNR1B
SCHEMBL15180088 0.80 CYP1A2 (0.40) SLC6A4CYP1A2CYP2D6
SCHEMBL3584957 0.78 SLC6A4 (0.56) SLC6A4HTR2AHTR6HTR2CHTR2B
SCHEMBL19980124 0.78 APLNR (0.41) PIK3CGMTNR1AMTNR1B
SCHEMBL11261059 0.78 POLB (0.56) CYP1A2MTNR1AMTNR1B
SCHEMBL23766356 0.75 APLNR (0.39) PIK3CGMTNR1AMTNR1B
SCHEMBL19776579 0.75 APLNR (0.46) CYP2D6
SCHEMBL13349450 0.75 SLC6A4 (0.52) SLC6A4HTR2AHTR6HTR2CHTR2B
SCHEMBL880881 0.74 SLC6A4 (0.46) SLC6A4HTR2AHTR6
SCHEMBL23671916 0.74 APLNR (0.44) SLC6A4HTR2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130211076-A1 Method for preparing substituted N-(3-amino-quinoxalin-2-yl)-sulfonamides and their intermediates N-(3-chloro-quinoxalin-2-yl)-sulfonamides MERCK SERONO S.A. GENEVA (CH) 2013-08-15 US disclosed
WO-2012052420-A1 METHOD FOR PREPARING SUBSTITUTED N-(3-AMINO-QUINOXALIN-2-YL)-SULFONAMIDES AND THEIR INTERMEDIATES N-(3-CHLORO-QUINOXALIN-2-YL)SULFONAMIDES MERCK SERONO S.A. GENEVA (CH) 2012-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130211076-A1 Method for preparing substituted N-(3-amino-quinoxalin-2-yl)-sulfonamides and their intermediates N-(3-chloro-quinoxalin-2-yl)-sulfonamides STS, NQO2, ASNS SLC6A4 1936/4885PIK3CG 2294/4885HTR2A 1387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.